Same Day HE4/Ovarian Cancer Sensitivity Ascot Clinic Test
On-site by appointment or same-day clinic walk-in. Our Same Day HPV test with HE4 / OC Sensitivity Blood checkup detects a biomarker to help diagnosis and indication of conditions.
HE4 is a protein located in the epithelial cells of the epididymis and influences fertility. HE4 is detected in smaller amounts in the normal epithelium of reproductive tract and ovary.
HE4 is found in large amounts of patients with ovarian cancer, therefore enabling use as a tumour marker in screening, which helps an oncologist in making a proper diagnosis. OC is a significant health problem and has a high mortality rate.
This exam detects a biomarker indicating the levels of:
Why should you do this HE4 HPV Test Clinic exam?
- Direct laboratory prices and support.
- Easy appointments.
- Fast results and prescriptions.
- HPV Variant 21
- CE-certified sensitive PCR laboratory equipment for accurate tests.
- MHRA-registered IVD devices.
- WhatsApp support during business hours.
How does the HPV HE4 clinic Appointment work?
Visit one of our HE4 test clinic locations.
Present an ID and order your appointment or simply walk-in.
Have your sample (blood) taken by staff to be tested.
Receive your results through email or by opening your dashboard on our site.
How long do I need to wait for my HE4 HPV Test Clinic results?
The typical turnaround time for the HE4 test is 1 working day. Do note that while we aim to give you results as quickly as possible, the exact result processing time may vary, following laboratory assays. We are committed to following strict guidelines to ensure quick and accurate HPV results. The close proximity of our laboratory to our clinic allows us to instantly analyze samples.
Please follow our eating and drinking guidelines before the day of sample collection.
Missed appointments are NOT REFUNDABLE. Similarly, cancellations done within 24 hours of the appointment time are NOT REFUNDABLE.
Please do not hesitate to discuss rescheduling and availability with us.
Disclaimer: We DO NOT draw blood samples from children under 16 years old.
Thank you for choosing our page using the search terms: ovarian cancer sensitivity blood test kit, ovarian cancer sensitivity test kit in the UK, and Ovarian cancer sensitivity home test,
What are the frequently asked Ovarian Cancer questions?
Q: What factors can lead to increased levels?
A: Renal insufficiency was the predominant source of false positive results. Patients with renal failure exhibited elevated levels compared to those with benign gynecological problems.
Q: What is the definition of elevated?
A: It may be present in elevated levels in patients with certain cancer forms, including ovarian epithelial carcinoma.
Q: What is it?
A: It is utilized to assist in the surveillance of recurrence or disease progression in individuals with epithelial ovarian cancer.
Q: Is fasting necessary?
A: Fasting is unnecessary.
Q: What occurs if the levels are elevated?
A: Elevated tumor markers indicate an increased probability of malignancy; nonetheless, a biopsy is generally necessary to verify or exclude the diagnosis.
The Scientific Data for HE4 from Our Suppliers:
Method:
Fluorescence quantitative immunoassay
Detection limits:
Less than or equal to 50.00 pmol/L.
Accuracy and Precision:
The relative standard deviation from the target value is ≤ 15%. The within assay CV is ≤ 15%. The between assay CV is ≤ 15%.
Measuring Range:
50.00~1000.00 pmol/L
Validation-Active Information:
- EQA:
- HPV
- Inter-laboratory validations
- Periodic according to the validation schedule.
- Event-triggered.
In range results:
The reference range for healthy females and males is less than 140 pmol/L.
Out-of-range results:
Any result greater than the reference range would be considered abnormal. Those with elevated levels of HE4 may be at risk for ovarian sensitivity cancer or other types of cancer.
Page Quality Review:
Review Date : 27/01/2026
Reviewed By :
In Between past and future HPV
Given the HPV World Day on 8 May, Nicole Colombo, director of the Gynaecology program at the IEO, responds to ACTO’s invitation by reviewing the progress made over the last decade in treating this serious neoplasm along with ca125 OC.
Precision medicine
“In recent years, there have been several new innovations for HPV treatments related cancer after years of total darkness,” stated Nicole Colombo. “Especially in the last five years, we have seen important advances, particularly in the first line of treatment. This is where the prognosis of the disease is at stake.”
For many years, precision medicine was only a mirage for ovarian-type tumours. It was not possible to identify targeted targets. This is because OC, or rather high-grade serous carcinoma, which is the most frequent in the advanced stage, does not exhibit specific mutations.
Drugs could directly target these mutations.
“CA125 type cancer exhibits a large genomic ‘chaos’ rather than one or more specific mutations,” states the expert. This has greatly limited us over the years in being able to use precision medicine – Colombo points out -. But in recent years, we have finally found a target. We understood that at least 50% of ovarian tumours have a defect in a DNA repair mechanism called homologous recombination.”
«At the beginning, we used PARP inhibitors for recurrent ovarian tumours, where they worked very well, delaying progression. But the great news of the last four or five years has been the demonstration that these drugs are extremely effective in the front line, that is, when we use them after the initial chemotherapy, following CA125 level surgery. If the tumour responds well to chemotherapy, we use PARP inhibitors as maintenance therapy. These drugs work very well in tumours with BRCA mutations and HRD tumours.”
The PARP inhibitor revolution
The explosion of PARP inhibitors began in 2018. Researchers demonstrated that their use in patients with BRCA mutations led to unprecedented benefits. These included increased progression-free survival and, very recently, improved overall survival.
“Long-term data indicate that patients receiving maintenance therapy with PARP inhibitors experience increased survival,” the expert notes. A study focusing exclusively on BRCA mutations revealed that 67% of the patients remained alive at seven years, compared to 46% in the placebo group. Additionally, 45% of the patients never relapsed, as opposed to 20% in the placebo group.
New combinations
New ideas for the ovarian disease also come from the combination of multiple drugs, as Colombo reports. In a study in which we combined the PARP inhibitor olaparib with bevacizumab a drug that blocks the growth of new vessels and therefore the nourishment of the tumour.
New weapons also for relapses
If it is true that the survival rate over HPV and the other diseases have increased, it is also true that there are also relapses. In this new class of drugs is emerging. And the antibody conjugatedrugs.
We can reach the Ca125 tumour with high concentrations of the drug and obtain a targeted effect and greater efficacy, as some tests have shown. Some of these drugs are being studied in ovarian research for cancer and have already demonstrated some effectiveness. One of these, mirvetuximab soravtansine, has received approval from the US Food and Drug Administration and we now hope it will also be approved by the European Medicines Agency. I think this is the most promising class of drugs for the future. Antibody drugs could make a difference in disease recurrence and persistence.
And the role of immunotherapy
In gynaecological tumours, immunotherapy has given excellent results for the endometrium and cervix. For the ovarian type disease, the trials have given negative results for now, reports Colombo. However, ongoing studies suggest a role, for example, in platinum-resistant disease or resistance to inhibitors. In recent years, we have brought immunotherapy to the forefront, continues Colombo.
We have conducted studies where, in addition to chemotherapy, we have administered immunotherapy along with the PARP inhibitor and bevacizumab. And just a few days ago, they announced that one of these trials had yielded positive results, better than the standard treatment.
So finally, there is a positive message for immunotherapy, even in the first line, at the beginning of the natural history of the disease.
The results will be presented at ASCO The importance of the Exam
The HPV has assumed a fundamental role in therapeutic decision-making. For first-line HPV treatment and other therapies because we observe the benefits of PARP inhibitors, especially in positive HRD cases.
Colombo confirms, HRD is a crucial predictive and prognostic factor. Therefore, having this information from the diagnosis stage is essential.Initially, an American company exclusively conducted this test, which was costly and impractical for widespread clinical use. However, various European academic initiatives aimed to develop a locally usable CA125 kit, and new commercial platforms emerged for laboratory use.
In collaboration with other Italian institutes, IEO has developed methods to conduct the HPV DNA exam. These methods are validated both in the laboratory and clinically on patients. Upon diagnosing cancer at IEO, the pathologist receives the sample. The pathologist not only performs the histological diagnosis but also conducts the BRCA and HRD tests.
External centers have the possibility of sending us their samples.
Furthermore, while waiting for recognition and reimbursement by the National CA125 Health System, we can count on the pharmaceutical industry’s support to carry out these investigations. There are no longer many excuses for not taking the exam in Italy,” concludes Colombo.
Shipping and Return Policies
Appointment:
Missed appointments or cancellations less than 24 hours prior are not entitled to refunds. Rescheduling is possible but not guaranteed. Please contact the customer service prior to the appointment time to discuss cost and availability options.
Shipping & Return:
We have a 14-day return policy, which means you have 14 days after receiving your item to request a return.
To Qualify for any return, the product must be in the same condition as when you received it. Not used, not opened, unworn, in its original packaging. You will also need to send it to us with the receipt or proof of purchase.
Please return to: Medicines by MailBox, 89 Falcon Rd, London. SW11 2PF
You can read our full return policy here:
https://medicinesbymailbox.co.uk/return-policy/
We offer next day delivery; however courier delivery times are out of our control. We are unable to offer refunds for any late deliveries. But you will receive courier tracking information once your order has been dispatched. And orders placed by 1pm are dispatched on the same day.
HE4 (o cancer sensitivity)
admin admin –
great support and fast results. i love them. they had helped me alot.
Lyna –
Highly recommend especially with the one day result time.
Lyna –
I booked an appointment but, had to cancel due to some family emergency. I contacted the customer and they were so accommodating and issued me a refund despite late cancellation.
Tessa W. –
What a breeze! Booking my appointment online was fast, and the staff greeted me with warm smiles.